{
    "organizations": [],
    "uuid": "f82cb5e3747acfa4d0b0971aa2e74aebabad660c",
    "author": "Charley Grant",
    "url": "https://www.wsj.com/articles/investors-are-overpaying-for-tevas-turnaround-1518105037",
    "ord_in_thread": 0,
    "title": "Investors Are Overpaying for Tevaâ€™s Turnaround",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "It is possible to imagine a bright future at Teva Pharmaceutical Industries for the first time in quite a while. There is no great need to rush into the stock, however.\nTeva announced that it expects sales of up to $18.8 billion and adjusted earnings of $2.25 to $2.50 a share in 2018. Wall Street analysts were looking for more, and the stock sold off sharply. The generic drugs giant has been grappling with a lot of problems, most notably a $32 billion debt load and falling prices on its U.S. products.\n...  ",
    "published": "2018-02-08T17:50:00.000+02:00",
    "crawled": "2018-02-08T18:47:39.028+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "possible",
        "imagine",
        "bright",
        "future",
        "teva",
        "pharmaceutical",
        "industry",
        "first",
        "time",
        "quite",
        "great",
        "need",
        "rush",
        "stock",
        "however",
        "teva",
        "announced",
        "expects",
        "sale",
        "billion",
        "adjusted",
        "earnings",
        "share",
        "wall",
        "street",
        "analyst",
        "looking",
        "stock",
        "sold",
        "sharply",
        "generic",
        "drug",
        "giant",
        "grappling",
        "lot",
        "problem",
        "notably",
        "billion",
        "debt",
        "load",
        "falling",
        "price",
        "product"
    ]
}